Kiavash Hushmandi – författare
Visar alla böcker från författaren . Handla med fri frakt och snabb leverans.
2 produkter
2 produkter
Inbunden, Engelska, 2025
4 214 kr
Skickas inom 3-6 vardagar
This book aims to provide a comprehensive exploration of three critical processes involved in cell death and survival, each playing a unique role in cancer development, progression, and treatment. Autophagy, apoptosis, and ferroptosis are distinct yet interconnected pathways that regulate cellular homeostasis and response to stress. In the context of oncology, these processes are of paramount importance. Cancer cells often manipulate autophagy and apoptosis to their advantage, evading death and promoting survival even in the face of therapeutic interventions.Understanding these mechanisms provides valuable insights into how cancer can be effectively targeted and treated. Furthermore, the emerging role of ferroptosis adds an exciting dimension to the ongoing quest for innovative cancer therapies. This book is structured to offer a detailed examination of each process, beginning with their fundamental biological mechanisms, followed by their implications in cancer biology.The chapters are designed to guide the reader through the intricate interplay between autophagy, apoptosis, and ferroptosis, highlighting recent discoveries, ongoing research, and potential therapeutic applications.
Inbunden, Engelska, 2026
2 296 kr
Skickas inom 3-6 vardagar
This book explores the groundbreaking potential of CRISPR/Cas9 gene-editing technology in revolutionizing cancer treatment. This collection of chapters delves into the application of CRISPR/Cas9 across a variety of cancers, including lung, breast, brain, gastric, pancreatic, colorectal, liver, prostate, bladder, cervical, ovarian, and bone cancers. Each chapter provides an in-depth analysis of how CRISPR/Cas9 can target and modify cancerous cells at the genetic level, offering the potential for highly personalized and precise therapies. The book also addresses the growing challenge of cancer drug resistance, detailing how CRISPR/Cas9 is being employed to study, understand, and potentially reverse resistance mechanisms, offering new hope for patients who have exhausted conventional treatment options. Furthermore, the integration of nanoparticles for efficient delivery of the CRISPR/Cas9 system is highlighted, providing a promising avenue for overcoming delivery challenges in cancer therapy.